Equities

Medinice SA

ICE:WSE

Medinice SA

Actions
Health CareMedical Equipment and Services
  • Price (PLN)12.12
  • Today's Change-0.28 / -2.26%
  • Shares traded307.18k
  • 1 Year change-27.86%
  • Beta--
Data delayed at least 15 minutes, as of Jul 26 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medinice SA is a Poland-based company engaged in medical diagnostic and testing equipment business sector. The Company specializes in creating, developing and commercializing safe and minimally invasive solutions in the field of medicine, in particular cardiology and cardio surgery. Its portfolio comprises of projects, such as CathAIO, Cryoapplicator, Med-IConsole, Minimax, Pacepress and others. All of the Company's projects have a global potential. The Company cooperates with research centers in Poland and Europe. It strives to commercialize inventions brought by both co-founders of the Company and acquired projects through the sale of licenses worldwide in the production of medical devices.

  • Revenue in PLN (TTM)225.00k
  • Net income in PLN-5.17m
  • Incorporated2012
  • Employees16.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Airway Medix SA11.00k-3.77m17.09m1.00------1,553.53-0.0582-0.05820.0002-0.19360.0018--0.046111,000.00-60.79-29.65---46.85-18.18---34,272.73-7,957.75---27.13-----87.37-58.0391.36------
CM International SA20.77m-2.86m19.37m38.00--2.53--0.9326-2.38-2.3817.266.370.81451.474.97432,667.70-11.236.06-17.8910.1743.2247.31-13.794.030.3705-10.570.00---8.5921.44-91.10-40.99-3.80--
Nestmedic SA1.17m-6.36m20.63m8.00--4.18--17.70-0.2748-0.27480.04990.17960.08940.10332.14129,486.70-48.83-57.10-83.17-115.3067.8847.37-545.99-519.421.27-16.160.1887---17.0866.94-36.68---60.10--
Inventionmed SA610.00-2.49m40.76m7.00--7.67--66,820.03-0.0123-0.01230.000.02620.00002--0.000690.10-6.89-17.52-12.24-22.72-11,611.48-48.77-408,403.30-42,256.86---2.140.00---85.01--91.47------
PZ Cormay SA84.43m-6.14m46.14m225.00--0.8482--0.5466-0.0729-0.07291.000.64610.87472.184.89375,240.00-6.39-12.12-9.76-17.1840.0639.19-7.31-16.500.7754-11.970.0765---3.673.3335.43---3.97--
Medinice SA225.00k-5.17m77.93m16.00--2.50--346.38-0.8224-0.82240.03594.970.0059--0.369814,062.50-13.46-12.47-13.77-12.9627.1162.64-2,297.33-1,404.30----0.017---10.71189.32-4.41--177.91--
Medicalgorithmics SA38.83m-6.10m282.66m120.00--3.19--7.28-0.6131-0.61313.908.910.32634.139.12323,541.70-5.13-0.9441-5.91-1.18-7.042.59-15.72-2.192.22-10.160.04510.00-31.28-26.39-102.27---18.81--
Data as of Jul 26 2024. Currency figures normalised to Medinice SA's reporting currency: Polish New Zloty PLN

Institutional shareholders

4.54%Per cent of shares held by top holders
HolderShares% Held
Allianz Polska TFI SAas of 31 Dec 2023133.47k2.07%
Norges Bank Investment Managementas of 31 Dec 2023130.00k2.01%
ESALIENS TFI SAas of 30 Jun 202030.00k0.46%
Data from 30 Jun 2020 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.